Tools   Select Another Resource Report Type

https://crispresso.pinellolab.partners.org/submission

Software suite of tools to qualitatively and quantitatively evaluate outcomes of genome editing experiments in which target loci are subject to deep sequencing and provides integrated, user friendly interface. Used for analysis of CRISPR-Cas9 genome editing outcomes from sequencing data. CRISPResso2 provides accurate and rapid genome editing sequence analysis.Used for analysis of deep sequencing data for rapid and intuitive interpretation of genome editing experiments.

Proper citation: CRISPResso (RRID:SCR_021538) Copy   

•   Source: SciCrunch Registry

https://labnodes.vanderbilt.edu/community/profile/id/1133

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 30,2023. Core facility that provides training and expertise in nutrition/diet methodology to obtain valid and reliable assessment and analyses of dietary intakes, nutritional status, body composition and metabolism.

Proper citation: Vanderbilt Diabetes Research and Training Center Vanderbilt Diet Body Composition and Metabolism Core Facility (RRID:SCR_010191) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT00100659

Multi-center, randomized controlled trial that studied peginterferon therapy, with or without ribavirin, in children with chronic hepatitis C. Approximately 120 children were randomly assigned to receive peginterferon alfa-2a alone or peginterferon with ribavirin for 48 weeks. Samples of blood, genomic DNA, and liver tissue are stored in the NIDDKrepositories. A long-term follow up study of the clinical trial participants is underway.

Proper citation: Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C (RRID:SCR_006787) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/ct2/show/NCT00688662

A prospective, double-blind, randomized, sham-controlled, multi-center clinical trial that enrolls subjects who have received a prior cholecystectomy and are diagnosed with the clinical syndrome of Sphincter of Oddi Dysfunction III (SOD III) as defined by the Rome III criteria. The goal of the study is to asses the value of endoscopic sphincterotomy as a treatment for adult subjects categorized as SOD III suffering from pain after cholecystectomy and to define the role of manometry in treating these patients.

Proper citation: Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (RRID:SCR_006897) Copy   

•   Source: SciCrunch Registry

http://archives.niddk.nih.gov/patient/camus/camus.aspx

Randomized, multicenter, double blind, placebo controlled clinical trial of phytotherapy for benign prostate symptoms among men. The CAMUS trial will test Saw palmetto in about 369 men. Men who decide to be part of the CAMUS trial will be given one out of two possible treatments at random. One out of every two men would get an inactive placebo treatment. One out of every two men would get Saw palmetto pills. This kind of scientific study is the best way to find out if the plant extracts really work to prevent men with benign prostatic hyperplasia (BPH) from getting worse. During the study, men will not know which of the two treatments they are assigned to. They will be followed very closely by a study team every 12 weeks to see how they are doing. Men in the CAMUS trial will be studied over 72 weeks. Ten clinical centers will participate in the trial. They are located at: Columbia University, NY, NY; New York University, NY, NY; University of Texas Southwestern Medical Center, Dallas, Texas; University of Colorado, Denver, CO; Washington University, St. Louis, MO; Yale University, New Haven, CT; Queens University, Hamilton, Ontario, Canada; Northwestern University, Chicago, IL; University of Maryland, Baltimore, MD; University of California at San Francisco, San Francisco, CA.

Proper citation: Complementary and Alternative Medicine for Urological Symptoms (RRID:SCR_007131) Copy   

•   Source: SciCrunch Registry

http://archives.niddk.nih.gov/patient/fsgs/fsgs.aspx

Network of collaborative research centers that tested the effects of treatment with cyclosporine to treatment with mycophenalate mofetil combined with oral pulse dexamethasone in children and young adults with focal segemental glomerulosclerosis. Efficacy was assessed in terms of induction of remission of proteinuria after 52 weeks of treatment and sustained remission after 26 weeks off treatment. The clinical sites were State University of New York, Stony Brook; Montefiore Medical Center; Seattle Children''''s Medical Center; Medical City Dallas Hospital; and the University of North Carolina. The Cleveland Clinic is the data-coordinating center, and NephCure will fund ancillary studies.

Proper citation: Focal Segmental Glomerulosclerosis in Children and Young Adults Interventional Study (RRID:SCR_007130) Copy   

•   Source: SciCrunch Registry

http://archives.niddk.nih.gov/patient/mist/mist.aspx

Randomized clinical trial to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin and finasteride. The study has been terminated. (Inability to recruit required sample size.)

Proper citation: Minimally Invasive Surgical Therapies Treatment Consortium for Benign Prostatic Hyperplasia (RRID:SCR_007126) Copy   

•   Source: SciCrunch Registry

http://www.med.upenn.edu/idom/drc/cores/cellbio.html

Core that gives support including experimental design, islet isolation, and performance of and training in an expansive range of assays for physiological and morphometric assessment of pancreatic islet function and growth. It contributes to the basic and translational research activities of the Institute of Diabetes, Obesity and Metabolism (IDOM) at the Perelman School of Medicine of the University of Pennsylvania. Its services include perform individual islet and single cell fluorescence imaging, respirometry with islet batches using a Seahorse Extracellular Flux Analyzer, perifusion coupled with respirometry, and closed respirometry experiments for our investigators.

Proper citation: University of Pennsylvania School of Medicine Penn Diabetes Research Center Pancreatic Islet Cell Biology Core Facility (RRID:SCR_008265) Copy   

•   Source: SciCrunch Registry

http://www.med.unc.edu/microbiome

Core facility that provides the research community with the facilities and the expertise to characterize complex microbial communities from different environments.Services offered by the Core include metagenomics methods to determine the composition and function of microbial communities using amplicon, Whole Genome Shotgun (WGS) and RNA sequencing, and traditional and high-throughput quantitative (q)PCR.

Proper citation: University of North Carolina Center for Gastrointestinal Biology and Disease Microbiome Core (RRID:SCR_012644) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT00143949

Randomized, multicenter, double-blind study to determine if renin angiotensin medications, either losartan (angiotensin II blocker) or enalapril (converting enzyme inhibitor), can prevent or delay the onset of diabetic kidney disease in patients with type 1 diabetic patients who do not have hypertension, diabetic nephropathy, or predictive levels of microalbuminuria. Two hundred eight five patients ages 16-61 with 2-20 yrs of Type 1 Diabetes Mellitus and no renal functional abnormalities were randomized into a parallel, double-blind, placebo-controlled study involving 3 groups (95 patients/group). Each group received an angiotensin-converting enzyme inhibitor (ACEI) (enalapril), or an angiotensin II receptor blocker (Losartan), or placebo. All patients had their usual Diabetes Mellitus (DM) management. Baseline studies included measures of glomerular filtration rate (GFR), urinary albumin excretion rate (UAE), blood pressure (BP), and a percutaneous renal biopsy. Patients were followed by quarterly measures of BP, HbA1C, UAE, and drug compliance. There were annual measures of GFR and a repeat renal biopsy after 5 yrs in the study. The main endpoint is kidney structural changes over time, especially mesangial fractional volume (v(Mes/glom)). Secondary endpoints will be other DN structural measures and measures of kidney function (UAE, GFR). These studies will determine whether rennin angiotensin system blockage in the early stages of DN can prevent the early kidney structural changes in this important disorder. Ancillary studies will evaluate the effects of treatment group on the development and progression of diabetic retinopathy and will develop predictors of study participants'''' compliance. Baseline, 2.5 and 5 year retinal fundus photographs in the RASS patients were obtained.

Proper citation: Renin Angiotensin System Study (RRID:SCR_013385) Copy   

•   Source: SciCrunch Registry

https://einsteinmed.edu/centers/diabetes-research/human-Islet-and-adenovirus-core/

Core which provides methodologies, technology and infrastructure to support investigators in the use of human islets for research studies for the Einstein-Mount Sinai Diabetes Research Center. It isolates and prepares human and rodent islets/beta cells and cell lines for investigator-initiated research and generates specific viral vectors (adenovirus and lentivirus) for gene delivery of cDNAs and shRNAs of interest to beta cells and other islet cell types.

Proper citation: Einstein-Mount Sinai Diabetes Research Center Human Islet and Adenovirus Core Facility (RRID:SCR_015066) Copy   

•   Source: SciCrunch Registry

https://einsteinmed.edu/research/shared-facilities/barc/

Core provides information and tools for Einstein and Montefiore investigators from initial study planning stage through analysis and data output. Facility services include: mass spectrometry analysis, including stable isotopes, as well as research-grade determination of lipids, and metabolic markers for human subjects and animal model projects; High-throughput robotics for semi-automated high-quality sample preparation and analysis by immunoassay and liquid chromatography–mass spectrometry (LC/MS); Support for novel developmental projects featuring applications of LC/MS and two-site bead-based assays; Research quality analysis of metabolites for human and animal samples using Olympus AU400 autoanalyzer; Advanced training in analytical chemistry.

Proper citation: Einstein-Mount Sinai Diabetes Research Center Biomarker Analytic Research Core Facility (RRID:SCR_015067) Copy   

•   Source: SciCrunch Registry

http://drc.ucsf.edu/mouse-genetics-core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on November 5,2024. Core that provides a shared resource for the establishment of mutant mouse models for DRC research. It coordinates DRC members with contacts to a number of UCSF-wide facilities for knock-out/knock-in and transgenic mouse generation.

Proper citation: University of California San Francisco Diabetes Research Center Mouse Genetics Core Facility (RRID:SCR_015109) Copy   

•   Source: SciCrunch Registry

http://www.uab.edu/shp/drc/administrative-core-links

Core responsible for the scientific, education/enrichment, and fiscal operations of the DRC. Their goal is to assure the growing vitality of an intellectual community and a highly productive research program in diabetes by effective deployment of DRC resources for the benefit of our investigators, patients, and trainees.

Proper citation: University of Alabama at Birmingham Diabetes Research Center Administrative Core Facility (RRID:SCR_015108) Copy   

•   Source: SciCrunch Registry

http://www.uab.edu/shp/drc/bioanalytical-redox-biology-core-barb-links

Core which promotes redox biology in diabetes-related research. It promotes research in areas common to the metabolic and vascular aspects of diabetes and cardiovascular disease. The core provides services in mitochondrial damage, function, proteomics, and oxidative stress assessment support for investigators carrying out diabetes mellitus (DM) and cardiometabolic disease (CMD) research at UAB.

Proper citation: University of Alabama at Birmingham Diabetes Research Center Bioanalytical REDOX Biology Core Facility (RRID:SCR_015113) Copy   

•   Source: SciCrunch Registry

https://www.derc.cuimc.columbia.edu/services/translational-biomarker-analytical-core

Core makes available to Diabetes Research Center investigators variety of high quality radio-immunoassay, ELISA, and other analytical methods, and facilitates access of DRC investigators to measurement of small molecules by targeted and untargeted metabolomics/lipidomics with the Irving Institute Biomarkers Core. TBAC also provides consultations and services for in vivo methods to measure insulin secretion and sensitivity.

Proper citation: Columbia Diabetes Research Center Translational Biomarker Analytical Core Facility (RRID:SCR_015077) Copy   

•   Source: SciCrunch Registry

http://www.uab.edu/shp/drc/human-physiology-core-links

Core which incorporates and combines expertise and technology for assessment of hormones and other analytes in both humans and animal models; body composition and fat distribution; insulin sensitivity and substrate metabolism; energy expenditure; and cardiovascular function.

Proper citation: University of Alabama at Birmingham Diabetes Research Center Human Physiology Core Facility (RRID:SCR_015111) Copy   

•   Source: SciCrunch Registry

http://www.hopkinsmedicine.org/diabetes-research-center/research-cores/genomics.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on November 6,2024. Core that provides services in genotyping, sequencing, biobanks, and genetic epidemiology. It also offers access to the Amish exome variant database, basic molecular services, and viral vector construction and development.

Proper citation: Johns Hopkins University - University of Maryland Diabetes Research Center Molecular and Translational Genomics Core (RRID:SCR_015116) Copy   

•   Source: SciCrunch Registry

http://diabetesresearch.med.umich.edu/Core_MDRC_OMICS.php

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on November 6,2024. Core that supports the use of the OMICS technologies by MDRC members (specifically on projects relevant to diabetes and related endocrine and metabolic disorders, including their complications) by supporting pilot studies that utilize these technologies.

Proper citation: Michigan Diabetes Research Center OMICS Core (RRID:SCR_015117) Copy   

•   Source: SciCrunch Registry

http://www.einstein.yu.edu/centers/diabetes-research/diabetes.aspx?id=1566&ekmensel=15074e5e_4046_4048_28715_1

Core which uses stable isotope flux and metabolite profiling to help formulate and test hypotheses about the metabolic consequences of various changes in gene expression and protein function, in order to guide further integrative systems biology analyses of the underlying mechanisms in diabetes, insulin resistance, obesity, and diabetic complications.

Proper citation: Einstein-Mount Sinai Diabetes Research Center Stable Isotope and Metabolomics Core Facility (RRID:SCR_015071) Copy   

•   Source: SciCrunch Registry